Compound Detail
CHEMBL290916
EDARAVONE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL290916 |
| Name | EDARAVONE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | QELUYTUMUWHWMC-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
10
Targets
22
Activities
2
Assay Types
18
PK Parameters
20
Publications
16
Known Names
7
Indications
1
Mechanisms
Molecular Properties
174.2
MW (Da)
1.80
ALogP
2
HBA
0
HBD
32.7
PSA (Ų)
0.64
QED
0
Ro5 Violations
1
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2017 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Unknown | - | - | ✓ | ✓ |
Indications
Amyotrophic Lateral Sclerosis Ischemic Stroke Brain Injuries Cerebral Hemorrhage Stroke Kidney Diseases Liver Diseases
ATC Classification
N07XX14
edaravone
Level 1: NERVOUS SYSTEM
Level 2: OTHER NERVOUS SYSTEM DRUGS
Activity Summary
IC50 18 meas. best 6.6
EC50 4 meas. best 5.53
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Unchecked CHEMBL612545 | IC50 | 6.6 | 5.0975 | 250.0 | 4 |
| Protein RecA CHEMBL1741171 | EC50 | 5.53 | 5.53 | 2950.0 | 1 |
| SH-SY5Y CHEMBL614910 | EC50 | 5.43 | 5.43 | 3750.0 | 1 |
| No relevant target CHEMBL2362975 | IC50 | 5.35 | 4.8975 | 4500.0 | 4 |
| Unchecked CHEMBL612545 | EC50 | 5.34 | 5.34 | 4610.0 | 1 |
| PC-12 CHEMBL612556 | EC50 | 5.04 | 5.04 | 9200.0 | 1 |
| Liver microsomes CHEMBL613694 | IC50 | 4.77 | 4.77 | 17000.0 | 1 |
| Brain CHEMBL613617 | IC50 | 4.74 | 4.74 | 18200.0 | 1 |
| Radical scavenging activity CHEMBL613712 | IC50 | 4.57 | 4.57 | 27000.0 | 1 |
| Rattus norvegicus CHEMBL376 | IC50 | 4.5 | 4.5 | 32000.0 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 CHEMBL3259476 | IC50 | 4.47 | 4.47 | 34000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 0.0008 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0036 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0018 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0037 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0013 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0785 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0453 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0033 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0007 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0424 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0017 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0016 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0002 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0164 | mL.min-1.g-1 | Homo sapiens |
| CL | 0.0084 | mL.min-1.g-1 | Homo sapiens |
| Cmax | 20000.0 | nM | Rattus norvegicus |
| Cmax | 6000.0 | nM | Homo sapiens |
| t1/2 | - | - | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine